Mylotarg(Gemtuzumab Ozogamicin) injection

Gemtuzumab ozogamicin is a drug used to treat FLT3-ITD-positive acute myeloid leukemia (AML). Main efficacy: 1. Induction of remission: Gemtuzumab ozogamicin is usually used for induction therapy of AML. It can help reduce the number of leukemia cells and induce AML to enter a state of remission. 2. Prolonging progression-free survival: Gemtuzumab ozogamicin treatment may prolong the progression-free survival of AML patients, that is, delay the progression of the disease. The drug has performed well in clinical trials, with significant efficacy and high safety.
1. Mechanism of action of Gemtuzumab ozogamicin

Gemtuzumab ozogamicin is a targeted therapy drug, mainly used for the treatment of acute myeloid leukemia (AML). It exerts its anti-tumor effect by binding to the CD33 antigen on the surface of leukemia cells. When Gemtuzumab ozogamicin binds to the CD33 antigen, it releases ozogamicin bound to the cell, thereby inhibiting the proliferation and survival of leukemia cells. This targeted therapy mechanism enables Gemtuzumab Ozomicin to effectively attack leukemia cells while reducing damage to normal cells.

2. Clinical application of Gemtuzumab Ozomicin

Gemtuzumab Ozomicin has made significant progress in the treatment of leukemia. Clinical studies have shown that compared with traditional chemotherapy regimens, Gemtuzumab Ozomicin combined with chemotherapy can improve the remission rate and survival rate of AML patients. In addition, Gemtuzumab Ozomicin can also be used to treat elderly AML patients or high-risk patients with other diseases, helping them to achieve better treatment results.